A2M is well presented at ISPOR 19th Annual European Congress, 29 October - 2 November 2016, Vienna, Austria with the following presentations by Dr. Mark Nuijten covering standard cost-effectiveness analyses, nutritioneconomics and financial valuation for medical innovatiion.
UK COST-EFFECTIVENESS ANALYSIS FOR MANAGEMENT OF CMV DISEASE IN PATIENTS POST ALLOGENEIC STEM CELL TRANSPLANTATION WITH A NOVEL ADOPTIVE T CELL THERAPY
EVALUATION OF METHODOLOGICAL VARIATIONS IN THE EVENT SIMULATION APPROACHES OF PUBLISHED HEALTH ECONOMIC MODELS IN OBESITY PREVENTION AND THERAPY
FOOD FOR THOUGHT (BUT NOT TOO MUCH) FOR HEALTH ECONOMIC ANALYSES OF NUTRITIONAL INTERVENTIONS IN OBESITY
ECONOMIC VALUATION OF ULTRA-INNOVATIVE DRUGS FROM A BROADER PERSPECTIVE
Evaluation and valuation of ultra-innovative drugs: a new concept
Mark Nuijten and Prof. Jan Vis published an interesting policy paper “ECONOMIC VALUATION OF ULTRA-INNOVATIVE DRUGS: A BROADER PERSPECTIVE”. July - August 2016 (2016). Value & Outcomes Spotlight.
Presentation of NICE model at European Hematology Association
Results of a study by Mark Nuijten, Catherine Kielar, Holger Müller and Carl Peggs were presented at the 21th congress of the European Hematology Association (EHA), June 9 - 12, 216 in Copenhagen, Denmark: COST-EFFECTIVENESS ANALYSIS OF A DIRECTLY SELECTED CMV-SPECIFIC T-CELL THERAPY FOR MANAGEMENT OF CMV DISEASE IN PATIENTS POST ALLOGENEIC STEM CELL TRANSPLANTATION: A UK ANALYSIS.
Valuation tool for biotechnology
Dr. Mark Nuijten (A2M) gave a lecture on “VALUATION OF HEALTHCARE INNOVATION: A DECISION ANALYTIC VALUATION MODEL FOR THE ASSESSMENT OF THE ECONOMIC VALUE OF AN INNOVATIVE MEDICINAL PRODUCT" for the European Biotechnology School, organized under auspices of the European Biotechnology Thematic Association (EBTNA) in Minsk, Belarius, May 29-June 3, 2016.xt
Valuation of innovation
Dr. Mark Nuijten (A2M) presented a new innovative tool for valuation of healthcare “VALUATION OF HEALTHCARE INNOVATION: A DECISION ANALYTIC VALUATION MODEL FOR THE ASSESSMENT OF THE ECONOMIC VALUE OF AN INNOVATIVE MEDICINAL PRODUCT" at the "European Biotechnology Congress 2016" in Riga, Latvia, on May 05-07, 2016.
Economics of obesity
Dr. Mark Nuijten presented “THE CHALLENGES OF HEALTH ECONOMIC ANALYSES OF NUTRITIONAL INTERVENTIONS IN OBESITY” at The European Obesity Summit, 1st and 4th of June 2016 in Gothenburg, Sweden.
Policy consultancy for Ministry of Health in The Netherlands
A2M participated in consortium headed by APE to give policy guidance to the Dutch Ministry of Health in The Netherland on the reimbursement levels for outpatient drugs. January - May. 2016. (Verdiepingsonderzoek Geneesmiddelenvergoedingssysteem (GVS) Onderzoek in opdracht van het Ministerie van Volksgezondheid, Welzijn en Sport).
EURORDIS Multi-stakeholder Symposium in Brussels
Dr. Mark Nuijten was panellist at the Multi-stakeholder Symposium on Improving Patient Access to Rare Disease Therapies, EURORDIS. 24-25 February 2016 in Brussels, Belgium.
Annual Meeting DGO in Berlin
Dr Mark Nuijten presented at the Annual Meeting of the German Health Economic Association: “COST-EFFECTIVENESS ANALYSIS OF ORPHAN MEDICINAL PRODUCTS: AN ALTERNATIVE APPROACH” at the DGGÖ 2016. Berlin, March 14-15, 2016, Germany.
Lecture at EURORDIS in PARIS
Dr. Mark Nuijten gave 1-day lecture at EURORDIS in Paris. “THE APPROPRIATENESS OF THE COST PER QALY IN THE DECISION-MAKING PROCESS. THE VALUE OF INNOVATION IN HEALTH CARE”. Paris, France, November 24, 2015.
New joint publications a2m with Nestle and Danone
Two new interesting publications in nutritioneconomics by Dr Nuijten. The 15Th for Danone during a 5 years collaboration and a new publication for Nestlé Nutrition Institute in textbook.
MJC Nuijten. Health economics in medical nutrition: an emerging science. Part of a Nestle textbook. The importance of nutrition as an integral part of disease management.
Bruyère F, Buendia-Jiménez I,Lenoir-Wijnkoop I, M, Nuijten MJ. Urinary tract infections: Economical impact of water intake]. Prog Urol. 2015. Sep;25(10):590-7.
Economic impact of macrosomia
Dr Nuijten, CEO of a2m, is a pioneer in the field of nutrition-economics and has been the first classical health economist applying and developing health economic methodologies to nutritionals. He is founder of the ISPOR Special Interest Group “Nutrition Economics” and recently published his 15th scientific paper in nutrition economics, titled “Health economic modelling to assess short-term costs of maternal overweight, gestational diabetes and related macrosomia” in Frontiers in Pharmacology. This pilot study shows the initial results of ongoing health economic modelling research projects in this area.
International Market Access Update
A2M contributed this year successfully to various reimbursement dossiers for Scotland, Austria, Ireland, Wales, Belgium and The Netherlands. A2M developed the cost-effectiveness and budget impact analyses and provided guidance on the overall reimbursement and market access strategy.